Bacterial artificial chromosomes

Patent metadata

Field	Value
Publication number	US-10076564-B2
Application number	US-201414787098-A
Country	US
Kind code	B2
Filing date	Apr 25, 2014
Priority date	Apr 26, 2013
Publication date	Sep 18, 2018
Grant date	Sep 18, 2018

Abstract

The invention relates to the use of a bacterial artificial chromosome (BAC) for the preparation of a vaccine, wherein the BAC comprises an inducible bacterial ori sequence for amplification of the BAC to more than 10 copies per bacterial cell. Plus a viral expression cassette comprising a cDNA of an attenuated RNA virus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.

First claim

The invention claimed is:

1. A method of preparing a vaccine against a flavivirus comprising the steps of:
a) providing a bacterial host transformed with a BAC (bacterial artificial chromosome) which comprises:
an inducible bacterial ori sequence for amplification of said BAC to more than 10 copies per bacterial cell, and
a viral expression cassette comprising a cDNA of an attenuated flavivirus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA,

b) amplifying the BAC by adding a compound which activates said inducible ori,
c) isolating the amplified BAC, and
d) formulating the BAC into a vaccine.

2. The method according to claim 1 , wherein said cDNA of the attenuated flavivirus genome is a chimeric viral cDNA construct of a flavivirus genome, wherein a heterologous DNA sequence has been inserted or wherein a native viral sequence has been deleted, truncated, or mutated.

3. The method according to claim 1 , wherein said viral expression cassette comprises:
a cDNA of a positive-strand flavivirus genome,
a RNA polymerase driven promoter preceding the 5′ end of said cDNA for initiating the transcription of said cDNA, and
an element for RNA self-cleaving following the 3′ end of said cDNA for cleaving the RNA transcript of said viral cDNA at a set position.

4. The method according to claim 1 , wherein said viral expression cassette comprises a cDNA of a yellow fever virus.

5. The method according to claim 1 , wherein said viral expression cassette comprises a cDNA of the live, attenuated YFV-17D yellow fever virus vaccine.

6. The method according to claim 1 , wherein said bacterial artificial chromosome further comprises a yeast autonomously replicating sequence for shuttling to and maintaining said bacterial artificial chromosome in yeast.

7. The method according to claim 6 , wherein said yeast autonomously replicating sequence is the 2μ plasmid origin or the ARS1 (autonomously replicating sequence 1) or functionally homologous derivatives thereof.

8. The method according to claim 3 , wherein said RNA polymerase driven promoter is an RNA polymerase II promoter.

9. The method according to claim 8 , wherein said RNA polymerase II promoter is the Cytomegalovirus Immediate Early (CMV-IE) promoter, the Simian virus 40 promoter or functionally homologous derivatives thereof.

10. The method according to claim 3 , wherein said RNA polymerase driven promoter is an RNA polymerase I or III promoter.

11. The method according to claim 3 , wherein said element for RNA self-cleaving is the cDNA of the genomic ribozyme of hepatitis delta virus or functionally homologous RNA elements.

12. The method according to claim 1 , wherein said viral expression cassette comprises a cDNA of the live, attenuated YFV-17D vaccine, wherein one or more of the cDNA sequences coding for the virion surface proteins are either deleted, truncated, or mutated so that such functional virion surface protein of YFV-17D is not expressed and wherein a cDNA sequence coding for a heterologous protein is inserted in the YFV-17D cDNA.

13. The method according to claim 12 , wherein said heterologous protein is a virion surface protein of a flavivirus.

14. The method according to claim 1 , wherein said viral expression cassette comprises a cDNA of the live, attenuated YFV-17D vaccine, wherein one or more unrelated cDNA sequences are inserted to be expressed as one or more heterologous protein within the viral polyprotein.

15. The method according to claim 1 , wherein said viral expression cassette comprises a viral cDNA wherein foreign cDNA sequences are inserted to be heterologously expressed.

16. A vaccine composition comprising a BAC, said BAC comprising:
an inducible bacterial ori sequence for amplification of said BAC to more than 10 copies per bacterial cell, and
a viral expression cassette comprising a cDNA of an attenuated flavivirus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.

17. A method of vaccination against a flavivirus infection comprising the step of administering a BAC, said BAC comprising:
an inducible bacterial ori sequence for amplification of said BAC to more than 10 copies per bacterial cell, and
a viral expression cassette comprising a cDNA of an attenuated flavivirus genome, or
a viral expression cassette comprising a cDNA of an attenuated flavivirus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.

18. A method for the maintenance of cDNA of a native or recombinant flavivirus genome or for the propagation of native or recombinant viruses from the cDNA, the method comprising the step of propagating a BAC in a bacterial host, the BAC comprising:
an inducible bacterial ori sequence for amplification of said BAC to more than 10 copies per bacterial cell, and
a viral expression cassette comprising a cDNA of an attenuated flavivirus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.

19. The vaccine according to claim 16 , wherein said attenuated flavivirus is a yellow fever virus.

20. The vaccine according to claim 19 , wherein said yellow fever virus is a live, attenuated YFV-17D yellow fever virus.

Assignees

• Univ Leuven Kath

Inventors

• Dallmeier Kai
• Neyts Johan

Classifications

• A61P31/14

  for RNA viruses · CPC title

• C12N15/69 Primary

  Increasing the copy number of the vector · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title